We are live on ! Find out more
AMAM

Ambrx Biopharma Inc
AMAM

Delisted

AMAM was delisted on the 6th of March, 2024.

Back to rankings

14 hedge funds and large institutions have $45.4M invested in Ambrx Biopharma Inc in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 14 → 14 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

4.67% less ownership

Funds ownership: 49.03% → 44.36% (-4.7%)

36% less capital invested

Capital invested by funds: $70.6M → $45.4M (-$25.2M)

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
6
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$123K
2
UBS Group
UBS Group
Switzerland
+$923

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$101K
2
Renaissance Technologies
Renaissance Technologies
New York
-$44.2K
3
Norges Bank
Norges Bank
Norway
-$29K
4
Morgan Stanley
Morgan Stanley
New York
-$12K
5
Millennium Management
Millennium Management
New York
-$6.3K

AMAM Hedge Fund Activity: Q2 2022 in Review

14 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q2 2022, worth a combined $45.4M — down 36% from $70.6M a quarter earlier.

Fund positioning in AMAM was balanced in Q2 2022: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 6 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $123K. The largest seller was Octagon Capital Advisors, cutting an estimated $101K.

  • 14 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $45.4M of Ambrx Biopharma Inc stock for Q2 2022, down 36% quarter-over-quarter.
  • 1 fund opened new Ambrx Biopharma Inc positions in Q2 2022 and 1 closed out, a net change of 0 holders.
  • The largest Ambrx Biopharma Inc buyer in Q2 2022 was Fidelity Investments, an estimated $123K added.
  • The largest Ambrx Biopharma Inc seller in Q2 2022 was Octagon Capital Advisors, an estimated $101K sold.

Based on aggregated 13F filings for Q2 2022.